Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study (vol 26, 1063, 2023)

被引：0

作者：

Kodera, Yasuhiro ^{[1
]}

Yoshida, Kazuhiro ^{[2
]}

Kochi, Mitsugu ^{[3
]}

Sano, Takeshi ^{[4
]}

Ichikawa, Wataru ^{[5
]}

Kakeji, Yoshihiro ^{[6
]}

Sunakawa, Yu ^{[7
]}

Takeuchi, Masahiro ^{[8
]}

Fujii, Masashi ^{[9
]}

机构：

[1] Nagoya Univ, Dept Surg Gastroenterol, Grad Sch Med, 65 Tsurumai Cho,Showa Ku, Nagoya, Aichi 4668550, Japan

[2] Gifu Univ, Dept Surg Oncol, Gifu, Japan

[3] Int Univ Hlth & Welf, Sch Med, Dept Hepatobiliary Pancreat & Gastrointestinal Su, Ichikawa, Japan

[4] Canc Inst Hosp, Gastroenterol Surg, Tokyo, Japan

[5] Showa Univ, Div Med Oncol, Fujigaoka Hosp, Yokohama, Kanagawa, Japan

[6] Kobe Univ, Div Gastrointestinal Surg, Dept Surg, Grad Sch Med, Kobe, Hyogo, Japan

[7] St Marianna Univ, Dept Clin Oncol, Sch Med, Kawasaki, Kanagawa, Japan

[8] Univ Tokyo, Grad Sch Math Sci, Tokyo, Japan

[9] Nihon Univ, Dept Digest Surg, Sch Med, Tokyo, Japan

来源：

GASTRIC CANCER | 2024年 / 27卷 / 05期

关键词：

D O I：

10.1007/s10120-024-01519-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1157 / 1157

页数：1

共 19 条

[1] Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study
Kodera, Yasuhiro
Yoshida, Kazuhiro
Kochi, Mitsugu
Sano, Takeshi
Ichikawa, Wataru
Kakeji, Yoshihiro
Sunakawa, Yu
Takeuchi, Masahiro
Fujii, Masashi
GASTRIC CANCER, 2023, 26 (06) : 1063 - 1068
[2] Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07
Kakeji, Yoshihiro
Yoshida, Kazuhiro
Kodera, Yasuhiro
Kochi, Mitsugu
Sano, Takeshi
Ichikawa, Wataru
Lee, Sang-Woong
Shibahara, Kazushige
Shikano, Toshio
Kataoka, Masato
Ishiguro, Atsushi
Ojima, Hitoshi
Sakai, Yoshinori
Musha, Nobuyuki
Takase, Tsunenobu
Kimura, Taisei
Takeuchi, Masahiro
Fujii, Masashi
GASTRIC CANCER, 2022, 25 (01) : 188 - 196
[3] Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07
Yoshihiro Kakeji
Kazuhiro Yoshida
Yasuhiro Kodera
Mitsugu Kochi
Takeshi Sano
Wataru Ichikawa
Sang-Woong Lee
Kazushige Shibahara
Toshio Shikano
Masato Kataoka
Atsushi Ishiguro
Hitoshi Ojima
Yoshinori Sakai
Nobuyuki Musha
Tsunenobu Takase
Taisei Kimura
Masahiro Takeuchi
Masashi Fujii
Gastric Cancer, 2022, 25 : 188 - 196
[4] Five-year overall survival with S-1 plus docetaxel as adjuvant treatment in curatively resected pStage III gastric cancer in JACCRO GC-07
Ichikawa, Wataru
Yoshida, Kazuhiro
Kodera, Yasuhiro
Kitazawa, Masato
Hirao, Motohiro
Seto, Yasuyuki
Hibi, Kenji
Kinami, Shinichi
Watanabe, Masaya
Makino, Shigeto
Kochi, Mitsugu
Sano, Takeshi
Kakeji, Yoshihiro
Takeuchi, Masahiro
Fujii, Masashi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial).
Kodera, Yasuhiro
Yoshida, Kazuhiro
Kochi, Mitsugu
Ichikawa, Wataru
Kakeji, Yoshihiro
Sano, Takeshi
Nagao, Narutoshi
Takahashi, Masazumi
Takagane, Akinori
Nakamura, Masanori
Kaji, Masahide
Okitsu, Hiroshi
Nomura, Takashi
Matsui, Takanori
Yoshikawa, Takaki
Matsuyama, Jin
Yamada, Makoto
Ito, Yuichi
Takeuchi, Masahiro
Fujii, Masashi
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Pre-planned feasibility and safety analyses of docetaxel/S-1 combination in a phase III study comparing docetaxel/S-1 with S-1 alone as postoperative adjuvant chemotherapy for stage III gastric cancer (JACCRO GC-07).
Kakeji, Yoshihiro
Kodera, Yasuhiro
Yoshida, Kazuhiro
Kochi, Mitsugu
Takahashi, Masazumi
Kii, Takayuki
Ishiguro, Atsushi
Ishigure, Kiyoshi
Takagane, Akinori
Matsui, Takanori
Kaji, Masahide
Ichikawa, Wataru
Sano, Takeshi
Takeuchi, Masahiro
Fujii, Masashi
Nakajima, Toshifusa
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[7] Confirmed three-year RFS and OS of the randomized trial of adjuvant S-1 versus S-1 plus docetaxel after curative resection of pStage III gastric cancer (JACCRO GC-07).
Yoshida, Kazuhiro
Kodera, Yasuhiro
Kochi, Mitsugu
Sano, Takeshi
Kakeji, Yoshihiro
Ichikawa, Wataru
Kurahashi, Shintaro
Yamaguchi, Hironori
Toyokawa, Takahiro
Nakamura, Masato
Fujitani, Kazumasa
Mochizuki, Yoshinari
Ota, Mitsuhiko
Hihara, Jun
Makari, Yoichi
Takeno, Atsushi
Takeuchi, Masahiro
Fujii, Masashi
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[8] Post-recurrent survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: A post-hoc analysis of the START-2 trial (JACCRO GC-07).
Ishida, Hiroo
Sunakawa, Yu
Kodera, Yasuhiro
Yoshida, Kazuhiro
Kochi, Mitsugu
Kakeji, Yoshihiro
Sano, Takeshi
Takeuchi, Masahiro
Ichikawa, Wataru
Fujii, Masashi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 371 - 371
[9] FIVE-YEAR OUTCOMES OF A PHASE II STUDY OF ADJUVANT CHEMOTHERAPY WITH S-1 PLUS DOCETAXEL FOR STAGE III GASTRIC CANCER AFTER CURATIVE D2 GASTRECTOMY
Shigeyuki, Tamura
Kazumasa, Fujitani
Yutaka, Kimura
Takeshi, Tsuji
Shohei, Iijima
Jin, Matsuyama
Hiroshi, Imamura
Kentarou, Inoue
Kenji, Kobayashi
Yukinori, Kurokawa
Toshio, Shimokawa
Toshimasa, Tsujinaka
Hiroshi, Furukawa
ANNALS OF ONCOLOGY, 2014, 25 : 40 - 40
[10] Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy
Fujitani, Kazumasa
Tamura, Shigeyuki
Kimura, Yutaka
Tsuji, Takeshi
Matsuyama, Jin
Iijima, Shohei
Imamura, Hiroshi
Inoue, Kentaro
Kobayashi, Kenji
Kurokawa, Yukinori
Shimokawa, Toshio
Tsujinaka, Toshimasa
Furukawa, Hiroshi
GASTRIC CANCER, 2014, 17 (02) : 348 - 353

← 1 2 →